COPD
IV mesenchymal stem cell and exosome protocols targeting the chronic inflammation that drives COPD progression. Patients in published umbilical-cord MSC trials have reported reduced exacerbations, improved breathlessness scores, and better quality of life.
- Class
- Pulmonary
- Approach
- IV systemic, multi-dose
- Materials
- MSC · exosome
- Coordination
- With pulmonology
01 About
What COPD is.
Chronic obstructive pulmonary disease (COPD) is a progressive respiratory condition combining chronic bronchitis and emphysema, driven primarily by long-term smoking and (less commonly) by genetic causes (alpha-1 antitrypsin deficiency) and environmental exposures. The chronic airway inflammation and parenchymal destruction lead to progressive airflow limitation and exercise intolerance.
Standard care is smoking cessation, inhaled bronchodilators, ICS/LABA/LAMA combinations, pulmonary rehabilitation, and (in advanced disease) supplemental oxygen and surgical interventions. Stem cell therapy is being studied as an adjunct — primarily targeting the chronic inflammatory drivers of progression.
02 How it works
How regen targets the lung.
Mesenchymal stem cells delivered systemically have well-documented anti-inflammatory effects in the lung. They modulate macrophage polarization, reduce proinflammatory cytokines (TNF-α, IL-6), and support tissue repair through paracrine signaling. For patients with COPD, the goal is to interrupt the chronic inflammatory cycle that drives ongoing parenchymal destruction.
Umbilical-cord-derived MSC protocols have produced the strongest published outcomes — reductions in exacerbation frequency, improved Modified Medical Research Council (mMRC) breathlessness scores, and meaningful gains in quality-of-life measures. This is the protocol family we anchor on.
03 What the research shows
What the studies show.
COPD has accumulated meaningful clinical-trial evidence — particularly for umbilical-cord-derived MSC protocols, which have produced the most consistent positive signals on patient-relevant endpoints (exacerbation rate, breathlessness, quality of life).
Umbilical-Cord MSC Transplantation Improves Quality of Life in COPD Patients
UC-MSC-transplanted COPD patients showed significantly reduced Modified Medical Research Council (mMRC) breathlessness scores, lower COPD assessment test (CAT) scores, and a significant decrease in the number of exacerbations versus baseline. Allogeneic non-HLA-matched umbilical-cord MSC transplantation improved measurable quality of life — the patient-relevant outcomes that matter most.
Read on Chinese Medical JournalMSC Administration in Patients with COPD
A comprehensive review of MSC therapy in COPD. The anti-inflammatory mechanisms are well-validated preclinically — MSCs modulate macrophage polarization, reduce TNF-α and IL-6, and support local tissue repair. Trials have established safety and identified the inflammation-driven patient subgroups (elevated CRP, frequent-exacerbator phenotype) most likely to respond.
Read on WileyMSC Administration in COPD: Systematic Review and Meta-Analysis
A systematic review and meta-analysis of preclinical MSC studies in COPD demonstrated consistent reductions in lung inflammation, alveolar destruction, and emphysematous change across animal models — providing the strong mechanistic foundation that has now translated into the human exacerbation and quality-of-life data.
Read on PubMed Central
The protocols that have shown the strongest patient-relevant outcomes use umbilical-cord-derived MSCs in repeat IV dosing — exactly the protocol family we use. We discuss expected outcomes (exacerbation reduction, breathlessness improvement, better quality of life) clearly before any commitment.
04 Are you a candidate
Who's a candidate.
Candidates:
- Moderate-to-severe COPD on optimized medical management with active pulmonology care.
- Patients who have stopped smoking and remain symptomatic despite inhaler therapy.
- Patients seeking adjunct anti-inflammatory therapy with realistic expectations.
- Stable medical status with no contraindications to IV cellular therapy.
When we will not recommend it:
- Active smokers — we will not provide therapy until smoking cessation is established.
- Acute COPD exacerbation — stabilize first, then revisit candidacy.
- End-stage disease where lung transplant evaluation is appropriate.
- Patients seeking to discontinue inhaler or pulmonology care.
Think you might be a candidate?
The first step is a 60–90 minute consultation. We review your imaging, history, and goals — and tell you honestly whether regenerative therapy is the right next step.
05 A patient experience
Dr. Abdullah is the doctor you'll want to have. Patient, calm, listens attentively. I'll wholeheartedly recommend this place to my family and loved ones.
Mickhail Bobga Google · 5.0
07What happens at your consultation
A conversation, not a sales meeting.
-
01
Intake & history
60–90 minutes. We review imaging, prior treatments, current medications, and goals. Most of this hour is listening.
-
02
Focused exam
A clinical exam tailored to your indication. Range of motion, strength, functional testing — what the literature actually predicts response on.
-
03
Honest candidacy review
If we think you're a candidate, we'll tell you why. If we don't, we'll tell you what we'd recommend instead — surgery, PT, watchful waiting.
-
04
Written plan & pricing
A defined treatment plan with modality, sequence, follow-up cadence, and total cost — before any commitment.
06 What treatment looks like
What treatment looks like.
A COPD protocol begins with pulmonology coordination, recent pulmonary function tests (spirometry, lung volumes, DLCO), and review of medications. Treatment is IV systemic MSC and/or exosome material in a series of monthly infusions, modeled on the protocols used in published trials.
Reassessment at 3, 6, and 12 months. Spirometry, exercise capacity testing (6-minute walk), CAT score, and ongoing pulmonology follow-up.
09 Common questions
Common questions, answered.
Do I need to stop smoking first?
Yes — always. We don't treat active smokers. Smoking cessation is non-negotiable for any regenerative protocol.
Will this replace my inhaler?
No. Inhalers and bronchodilators stay; regenerative therapy is adjunctive.
What outcomes can I expect?
Reduced exacerbation frequency, improved breathlessness scores (mMRC), and better quality of life — based on published umbilical-cord MSC trial data.
How is this different from pulmonary rehab?
They work together. PR builds capacity; regenerative therapy targets underlying inflammation. Both have a place.
Is this safe with my oxygen therapy?
Generally yes. We review your full pulmonology regimen before scheduling.
What are the risks?
IV MSC protocols are consistently well-tolerated in COPD trials. No serious adverse events linked to MSC administration in the major published RCT.
08 Coverage & cost
Most regenerative protocols at Apex are not covered by insurance — we discuss pricing directly, in writing, before any commitment. Softwave shockwave is the exception: covered by Medicare Parts A & B with supplement (not by Medicare Advantage). Financing options are available for protocols not covered. We never hold a pricing conversation until we know you're a candidate.
Begin with a consultation.
A frank conversation about your COPD, what the published trials actually show, and whether IV MSC therapy is the right addition to your existing pulmonology care.